255 related articles for article (PubMed ID: 20682656)
1. Galectin-3 promotes chronic activation of K-Ras and differentiation block in malignant thyroid carcinomas.
Levy R; Grafi-Cohen M; Kraiem Z; Kloog Y
Mol Cancer Ther; 2010 Aug; 9(8):2208-19. PubMed ID: 20682656
[TBL] [Abstract][Full Text] [Related]
2. Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition.
Charette N; De Saeger C; Lannoy V; Horsmans Y; Leclercq I; Stärkel P
Mol Cancer; 2010 Sep; 9():256. PubMed ID: 20860815
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of malignant thyroid carcinoma cell proliferation by Ras and galectin-3 inhibitors.
Menachem A; Bodner O; Pastor J; Raz A; Kloog Y
Cell Death Discov; 2015; 1():15047. PubMed ID: 27551476
[TBL] [Abstract][Full Text] [Related]
4. Disruption of cooperation between Ras and MycN in human neuroblastoma cells promotes growth arrest.
Yaari S; Jacob-Hirsch J; Amariglio N; Haklai R; Rechavi G; Kloog Y
Clin Cancer Res; 2005 Jun; 11(12):4321-30. PubMed ID: 15958613
[TBL] [Abstract][Full Text] [Related]
5. Ras inhibits endoplasmic reticulum stress in human cancer cells with amplified Myc.
Yaari-Stark S; Shaked M; Nevo-Caspi Y; Jacob-Hircsh J; Shamir R; Rechavi G; Kloog Y
Int J Cancer; 2010 May; 126(10):2268-81. PubMed ID: 19998334
[TBL] [Abstract][Full Text] [Related]
6. The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1.
Barkan B; Starinsky S; Friedman E; Stein R; Kloog Y
Clin Cancer Res; 2006 Sep; 12(18):5533-42. PubMed ID: 17000690
[TBL] [Abstract][Full Text] [Related]
7. K-ras nanoclustering is subverted by overexpression of the scaffold protein galectin-3.
Shalom-Feuerstein R; Plowman SJ; Rotblat B; Ariotti N; Tian T; Hancock JF; Kloog Y
Cancer Res; 2008 Aug; 68(16):6608-16. PubMed ID: 18701484
[TBL] [Abstract][Full Text] [Related]
8. Phenotypic reversion of invasive neurofibromin-deficient schwannoma by FTS: Ras inhibition reduces BMP4/Erk/Smad signaling.
Barkan B; Kloog Y; Ehrlich M
Mol Cancer Ther; 2011 Aug; 10(8):1317-26. PubMed ID: 21632464
[TBL] [Abstract][Full Text] [Related]
9. [Expression of TTF-1 in thyroid tumors originating from follicular epithelium and its correlation with expression of RET, galectin-3 and mucin-1 genes].
Chen Y; Zhu M; Zhou X; Lin W; Ni C; Li F; Zhang S; Gong Z
Zhonghua Yi Xue Za Zhi; 2002 Feb; 82(4):257-61. PubMed ID: 11953175
[TBL] [Abstract][Full Text] [Related]
10. The inhibition of human mesangial cell proliferation by S-trans, trans-farnesylthiosalicylic acid.
Khwaja A; Sharpe CC; Noor M; Kloog Y; Hendry BM
Kidney Int; 2005 Aug; 68(2):474-86. PubMed ID: 16014024
[TBL] [Abstract][Full Text] [Related]
11. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.
Piscazzi A; Costantino E; Maddalena F; Natalicchio MI; Gerardi AM; Antonetti R; Cignarelli M; Landriscina M
J Clin Endocrinol Metab; 2012 Jun; 97(6):E898-906. PubMed ID: 22442268
[TBL] [Abstract][Full Text] [Related]
12. Ras inhibition in hepatocarcinoma by S-trans-trans-farnesylthiosalicyclic acid: association of its tumor preventive effect with cell proliferation, cell cycle events, and angiogenesis.
Stärkel P; Charette N; Borbath I; Schneider-Merck T; De Saeger C; Abarca J; Leclercq I; Horsmans Y
Mol Carcinog; 2012 Oct; 51(10):816-25. PubMed ID: 21882255
[TBL] [Abstract][Full Text] [Related]
13. New derivatives of farnesylthiosalicylic acid (salirasib) for cancer treatment: farnesylthiosalicylamide inhibits tumor growth in nude mice models.
Goldberg L; Haklai R; Bauer V; Heiss A; Kloog Y
J Med Chem; 2009 Jan; 52(1):197-205. PubMed ID: 19072665
[TBL] [Abstract][Full Text] [Related]
14. Ras inhibition results in growth arrest and death of androgen-dependent and androgen-independent prostate cancer cells.
Erlich S; Tal-Or P; Liebling R; Blum R; Karunagaran D; Kloog Y; Pinkas-Kramarski R
Biochem Pharmacol; 2006 Aug; 72(4):427-36. PubMed ID: 16780807
[TBL] [Abstract][Full Text] [Related]
15. Galectin-3 augments K-Ras activation and triggers a Ras signal that attenuates ERK but not phosphoinositide 3-kinase activity.
Elad-Sfadia G; Haklai R; Balan E; Kloog Y
J Biol Chem; 2004 Aug; 279(33):34922-30. PubMed ID: 15205467
[TBL] [Abstract][Full Text] [Related]
16. Ras inhibition by FTS attenuates brain tumor growth in mice by direct antitumor activity and enhanced reactivity of cytotoxic lymphocytes.
Aizman E; Mor A; Levy A; George J; Kloog Y
Oncotarget; 2012 Feb; 3(2):144-57. PubMed ID: 22323550
[TBL] [Abstract][Full Text] [Related]
17. A novel Ras antagonist regulates both oncogenic Ras and the tumor suppressor p53 in colon cancer cells.
Halaschek-Wiener J; Wacheck V; Schlagbauer-Wadl H; Wolff K; Kloog Y; Jansen B
Mol Med; 2000 Aug; 6(8):693-704. PubMed ID: 11055588
[TBL] [Abstract][Full Text] [Related]
18. Galectin-3 mediates cross-talk between K-Ras and Let-7c tumor suppressor microRNA.
Levy R; Biran A; Poirier F; Raz A; Kloog Y
PLoS One; 2011; 6(11):e27490. PubMed ID: 22102901
[TBL] [Abstract][Full Text] [Related]
19. HRAS as a potential therapeutic target of salirasib RAS inhibitor in bladder cancer.
Sugita S; Enokida H; Yoshino H; Miyamoto K; Yonemori M; Sakaguchi T; Osako Y; Nakagawa M
Int J Oncol; 2018 Aug; 53(2):725-736. PubMed ID: 29901113
[TBL] [Abstract][Full Text] [Related]
20. The Ras-pathway inhibitor, S-trans-trans-farnesylthiosalicylic acid, suppresses experimental allergic encephalomyelitis.
Karussis D; Abramsky O; Grigoriadis N; Chapman J; Mizrachi-Koll R; Niv H; Kloog Y
J Neuroimmunol; 2001 Nov; 120(1-2):1-9. PubMed ID: 11694313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
